Estimates Revisions Vanda Pharmaceuticals Inc.
Equities
VNDA
US9216591084
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.230 USD | -0.64% |
|
-16.05% | -29.66% |
| May. 07 | Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026 | |
| May. 06 | Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Equities
- VNDA Stock
- Consensus Vanda Pharmaceuticals Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
